Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Dr. Reddy's Laboratories has kicked off FY26 with double-digit growth. M.V. Ramana, CEO of Branded Markets (India & Emerging Markets), breaks down how the pharma major is evolving its strategy beyond ...

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddy’s Laboratories ( ($RDY) ) has issued an update. On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the ...

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday reported profit of $165 million in its fiscal first quarter. On a per-share basis, the Hyderabad, India ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...